Treatment of Primary Focal and Segmental Glomerulosclerosis

Document Type : Original Article

Authors

1 Chronic Renal Failure Research Center, Department of Pediatric Nephrology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Chronic Renal Failure Research Center, Department of Nephrology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Abstract

Focal segmental glomerulosclerosis (FSGS) is a common cause of nephrotic syndrome in adults and children. It may occur either without an identifiable cause (idiopathic or primary) or in response to previous glomerular injury (secondary). In the treatment of FSGS distinguishing between primary and secondary is important because immunosuppressive therapy is indicated in most patients with primary FSGS but not in secondary FSGS. Untreated patients with primary FSGS who present with nephrotic range proteinuria (proteinuria>3.5 g/day) and hypoalbuminemia typically have a progressive course to end stage renal disease. It appears that primary FSGS is responded to prednisone at a dose of 1 mg/kg per day (maximum dose 60 to 80 mg/day) in 40 to 80 % of patients, however prolonged glucocorticoid therapy for a minimum of 12 to 16 weeks is generally required to induce remission among these patients. For the treatment of steroid-resistant or relapsing disease, cyclosporine is most commonly used at a dose of approximately 2 to 4 mg/kg per day (given in two divided doses) in conjunction with low dose of prednisone (maximum 15 mg/day). In addition, other agents, including cyclophosphamide and mycophenolatemofetile have also been tried among steroid-resistant or relapsing disease with various degrees of response.

Keywords

References

1-Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis1999;34(5):795–808.
2-Beladi Musavi SS,  Hayati F, Talebnejad M, Mousavi M. What is the difference between causes of ESRD in Iran and developing countries? Shiraz E-Med J [Serial Online] 2012;13(2). Available from: URL: http://semj.sums.ac.ir/vol13/apr2012/90016.htm. Accessed on month day, year.
3-Beladi Musavi SS,  Hayati F, Alemzadeh Ansari MJ, Valavi E, Cheraghian B, Shahbazian HA, et al. Survival at 1, 3, and 5 Years in Diabetic and Nondiabetic Hemodialysis Patients. Iran J Kidney Dis 2010;4(1):74-7.
4-Perneger TV, Brancati FL, Whelton PK, Klag MJ. End-stage renal disease attributable to diabetes mellitus. Ann Intern Med 1994;121(12):912-8.
5-Hsu CY, Vittinghoff E, Lin F, Shlipak MG. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med. 2004;41(2):95-101.
6-Beladi Musavi SS,  Sametzadeh M, Hayati F, Fatemi SM. Evaluation of acquired cystic kidney disease in patients on hemodialysis with ultrasonography. Iran J Kidney Dis 2010;4(3):223-6.
7-Van Dijk PC, Jager KJ, Stengel B, Grönhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 2005;67(4):1489-99.
8-Haghighi AN,  Broumand B,  D'Amico M, Locatelli F, Ritz E. The epidemiology of end-stage renal disease in Iran in an international perspective.  Nephrol Dial Transplant 2002;17(1):28-32.
9-Malekmakan L, Haghpanah S, Pakfetrat M, Malekmakan A, Khajehdehi P. Causes of chronic renal failure among Iranian hemodialysis patients.  Saudi J Kidney Dis Transpl 2009;20(3):501-4.
10-Aghighi M, Mahdavi-Mazdeh M, Zamyadi M, Heidary Rouchi AR,  Rajolani H, Nourozi S. Changing epidemiology of end-stage renal disease in last 10 years in Iran. Iran J Kidney Dis 2009;3(4):192-6.
11-Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997;30(5):621-31.
12-Beladi Musavi SS. Cause of primary nephrotic syndrome in adult patients in Khuzestan province. Abstract book of the 12th International Congress of Nephrology, Dialysis and Transplantation, Iran J Kidney Dis 2009;3:75.
13-Braden GL, Mulhern JG, O'Shea MH, , Nash SV, Ucci AA Jr, Germain MJ. Changing incidence of glomerular diseases in adults. Am J Kidney Dis 2000;35(5):878-83.
14-Beladi Musavi SS, Hayati F, Shahbazian H. [Is the prevalence of focal and segmental glomerulosclerosis increasing in the Province of Khuzestan?] Jundishapur Sci Med J 2012;11(2):157-62. [In Persian]
15-Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 2004;44(5):815-25.
16-Bahiense-Oliveira M, Saldanha LB, Mota EL, Penna DO, Barros RT, Romão-Junior JE. Primary glomerular diseases in Brazil (1979-1999): is the frequency of focal and segmental glomerulosclerosis increasing? Clin Nephrol 2004;61(2):90-7.
17-Filler G, Young E, Geier P, Carpenter B, Drukker A, Feber J. Is there really an increase in non-minimal change nephrotic syndrome in children? Am J Kidney Dis 2003;42(6):1107-13.
18-Korbet SM, Genchi RM, Borok RZ, Schwartz MM. The racial prevalence of glomerular lesions in nephrotic adults. Am J Kidney Dis 1996;27(5):647-51.
19-D'Agati V. The many masks of focal segmental glomerulosclerosis. Kidney Int 1994;46(4):1223-41.
20-Praga M, Morales E, Herrero JC, Pérez Campos A, Domínguez-Gil B, Alegre R, et al. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am J Kidney Dis 1999;33(1):52-8.
21-Praga M, Hernández E, Montoyo C, Andrés A, Ruilope LM, Rodicio JL. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992;20(3):240-8.
22-Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989;36(2):272-9.
23-Ferder LF, Inserra F, Daccordi H, Smith RD. Enalapril improved renal function and proteinuria in chronic glomerulopathies. Nephron 1990; 55 Suppl 1:90-5.
24-Crenshaw G, Bigler S, Salem M, Crook ED. Focal segmental glomerulosclerosis in African Americans: effects of steroids and angiotensin converting enzyme inhibitors. Am J Med Sci 2000;319(5):320-5.
25-Stiles KP, Abbott KC, Welch PG, Yuan CM. Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic. Clin Nephrol 2001;56(2):89-95.
26-Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998;32(1):72-9.
27-Chitalia VC, Wells JE, Robson RA, Searle M, Lynn KL. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. Kidney Int 1999;56(6):2236-42.
28-Banfi G, Moriggi M, Sabadini E, Fellin G, D'Amico G, Ponticelli C. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 1991;36(2):53-9.
29-Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004;15(8):2169-77.
30-Nash MA, Greifer I, Olbing H, Bernstein J, Bennett B, Spitzer A. The significance of focal sclerotic lesions of glomeruli in children. J Pediatr 1976;88(5):806-13.
31-Ponticelli C, Villa M, Banfi G, Cesana B, Pozzi C, Pani A, et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 1999;34(4):618-25.
32-Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 2005;16(4):1061-8.
33-Thomas DB, Franceschini N, Hogan SL, Ten Holder S, Jennette CE, Falk RJ, et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006;69(5):920-6.
34-Beaman M, Howie AJ, Hardwicke J, Michael J, Adu D. The glomerular tip lesion: a steroid responsive nephrotic syndrome. Clin Nephrol 1987;27(5):217-21.
35-Winn MP, Conlon PJ, Lynn KL, Howell DN, Slotterbeck BD, Smith AH, et al. Linkage of a gene causing familial focal segmental glomerulosclerosis to chromosome 11 and further evidence of genetic heterogeneity. Genomics 1999;58(2):113-20.
36-Pollak MR. The genetic basis of FSGS and steroid-resistant nephrosis. Semin Nephrol 2003;23(2):141-6.
37-Ruf RG, Lichtenberger A, Karle SM, Haas JP, Anacleto FE, Schultheiss M, et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004;15(3):722-32.
38-Heering P, Braun N, Müllejans R, Ivens K, Zäuner I, Fünfstück R, et al. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis 2004;43(1):10-8.
39-Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993;43(6):1377-84.
40-Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr 1994;125(6 Pt1):981-6.
41-Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 1996;7(1):56-63.
42-Duncan N, Dhaygude A, Owen J, Cairns TD, Griffith M, McLean AG, et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant 2004;19(12):3062-7.
43-Segarra A, Vila J, Pou L, Arbós A, Quiles T, Piera LL. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 2002;17(4):655-62.
44-Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol 2004;19(3):281-7.
45-Li X, Li H, Ye H, Li Q, He X, Zhang X, et al. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis 2009;54(1):51-8.
46-Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011;80(8):868-78.
47-Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61(3):1098-114.
48-Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D. Mycophenolatemofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002;17(11):2011-3.
49-Montané B, Abitbol C, Chandar J, Strauss J, Zilleruelo G. Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 2003;18(8):772-7.
50-Cattran DC, Wang MM, Appel G, Matalon A, Briggs W. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004;62(6):405-11.
51-Deegens JK, Wetzels JF. Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial. Kidney Int 2011;80(8):798-801.
52-Siegel NJ, Gaudio KM, Krassner LS, McDonald BM, Anderson FP, Kashgarian M. Steroid-dependent nephrotic syndrome in children: histopathology and relapses after cyclophosphamide treatment. Kidney Int 1981;19(3):454-9.
53-Schulman SL, Kaiser BA, Polinsky MS, Srinivasan R, Baluarte HJ. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J Pediatr 1988;113(6):996-1001.
54-Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie. Arch Dis Child 1987;62(11):1102-6.
55-Tumlin JA, Miller D, Near M, Selvaraj S, Hennigar R, Guasch A. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2006;1(1):109-16.
56-Cho M, Hurley JK, Kopp JB. Sirolimus for focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis. 2007;49(2):310-7
57-Cho ME, Hurley JK, Kopp JB. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis 2007;49(2):310-7.
58-Fervenza FC, Fitzpatrick PM, Mertz J, Erickson SB, Liggett S, Popham S, et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 2004;19(5):1288-92.
59-Ginsburg DS, Dau P. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis. Clin Nephrol 1997;48(5):282-7.
60-Mitwalli AH. Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis? Nephrol Dial Transplant 1998;13(6):1524-8.
61-Feld SM, Figueroa P, Savin V, Nast CC, Sharma R, Sharma M, et al. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis 1998;32(2):230-7.
62-Godfrin Y, Dantal J, Bouhours JF, Heslan JM, Soulillou JP. A new method of measuring albumin permeability in isolated glomeruli. Kidney Int 1996;50(4):1352-7.
Jundishapur Scientific Medical Journal
Volume 12, Issue 6 - Serial Number 87
July and August 2013
Pages 645-653

Files

History

  • Receive Date: 21 July 2012
  • Revise Date: 17 April 2013
  • Accept Date: 22 June 2013

Share

How to cite

Statistics